US5939076A - Composition and method for treating or alleviating migraine headaches - Google Patents
Composition and method for treating or alleviating migraine headaches Download PDFInfo
- Publication number
- US5939076A US5939076A US08/968,358 US96835897A US5939076A US 5939076 A US5939076 A US 5939076A US 96835897 A US96835897 A US 96835897A US 5939076 A US5939076 A US 5939076A
- Authority
- US
- United States
- Prior art keywords
- calcium
- magnesium
- formulation
- vitamin
- formulation comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Definitions
- This invention relates to a method for preventing or alleviating migraine headaches and compositions therefor. More particularly, this invention relates to compositions and methods for preventing or alleviating migraine headaches through vasomotor control.
- Migraine headaches are the most severe or intensive type of headaches and affect approximately fifteen percent of the population. This disdorder is highly disruptive of the life of a sufferer thereof and also results in a very significant amount of lost work time. Moreover, there has been no really effective way to prevent the onset of such migraine headaches.
- the migraine attack has two main phases, namely the aural phase and the acute painful headache phase.
- Several symptons occur during the aural phase, such as visual scotomata (absence of vision within the visual field), spots, scintillating (flashing) visual scotomata, and other visual disturbances.
- the migraine sufferer may become tired and possibly faint.
- a throbbing hemi-cranial pain develops, either on one side, the front or the rear of the head.
- Other symptoms such as nausea or diarrhea may occur during a severe migraine headache.
- Migraine headaches develop suddenly and reach an intense level quickly.
- pharmacological agents have been employed in attempts to treat a person suf fering from migraine headaches.
- these pharmacological agents have been employed to treat the symptoms of a migraine headache after the onset or occurrence of the acute painful headache phase.
- pharmacological agents suggested for treatment of migraine headaches are antihistamines in combination with analgesics, vasodialators such as papaverine, beta-andrenergic blockers such as propranolol, nadolol, timolol and antenolol, calcium channel antagonists, and various phenothiazines.
- Extracranial vasoconstrictors such as ergot alkaloids, for example, ergotamine and sumatriptan, have also been employed since it has been considered that increased levels of norepinephrine, seratonin, bradykinin and substance P were considered to be the endogenous pain-producing compounds in combination with stretching due to vasoconstriction and vasodilation resulting as a reflex action to a variety of stimuli, such as intense light, noise, anxiety, exertion, cold, heat, hormones, and certain foods.
- stimuli such as intense light, noise, anxiety, exertion, cold, heat, hormones, and certain foods.
- a daily supplementation of precursors for the neurotransmitters serotonin and norepinephrine is provided in order to increase the average daily levels of these neurotransmitters and thereby prevent or inhibit a drop in sero-tonin and norepinephrine levels in the brain to levels causing loss of vasomotor control and in that manner avoid the onset of a migraine headache.
- the precursors may be administered with one or more of other ancillary agents such as bioflavanoids, antioxidants, methyl donors, anti-allergic substances, cell membrane support substances, sources of copper, calcium, magnesium and niacin, vitamin C, vitamin B6, choline and folic acid.
- patients are administered daily supplements of precursors for the neurotransmitters serotonin and norepinephrine to maintain or elevate brain levels of these neurotransmitters so that the levels thereof are prevented or inhibited from falling below the level causing loss of vasomotor control by the hypothalmus of various circulatory paths to the brain.
- the daily supplementation of precursors for serotonin and norepinephrine comprises administering, for an effective daily period, an effective amount of L-tryptophan or L-5-hydroxytryptophan as the precursors for serotonin and L-tyrosine as the precursor for norepinephrine.
- the serotonin precursor is generally taken at bedtime, generally about 3 to 4 hours after the last meal of the day and is most preferably taken with cold fruit juice.
- the norepinephrine precursor is taken during the day, generally with food.
- the daily supplement of serotonin precursor include an effective amount of at least one carbohydrate, such as fructose, corn starch or dextrose, to stimulate the production of insulin to facilitate absorption of the serotonin precursor across the blood brain barrier. It is also desirable that the daily supplement of serotonin precursor include an effective amount of niacin, such as inositol hexanicotinate, to insure that the serotonin precursor is not converted to niacin instead of serotonin. The niacin also is useful for vasomotor control. Additionally, it is desirable to include an effective amount of pyridoxine HCl (vitamin B6) to inhibit tryptophan oxygenase which metabolizes tryptophan.
- pyridoxine HCl vitamin B6
- the daily supplement of precursors for serotonin and norepinephrine can include therewith effective amounts of various other components.
- these other components can be present with either the daily supplement of the serotonin precursor or the norepinephrine precursor or with both supplements.
- these other components are the following components.
- vitamin C an effective amount of vitamin C, an antioxidant, and proanthocyanidins, an antioxidant and antihistimine, are generally included to help reduce allergic reactions causing loss of serotonin and norepinephrine.
- the vitamin C is also helpful in the production of norepinephrine from tyrosine and the proanthocyanidins as a collagen protector to hold together the cells of the blood vessel wall and blood brain barrier.
- the vitamin C source e.g. calcium ascorbate
- the proanthocyanidins to preferably present with the norepinephrine precursor supplement.
- a bioflavanoid such as quercitin, rutin or hexperidin
- an effective amount of a bioflavanoid is included to strengthen outer cell membranes and help stabilize the cell surface and to stabilize the cell walls of basophils and mast cells, so they will not burst easily and release histimine and other inflammatory chemicals in the patient.
- the bioflavanoid is quercitin and the bioflavanoid is preferably included with the norepinephrine precursor supplement.
- calcium e.g. as calcium citrate
- magnesium e.g. magnesium citrate or aspartate
- both the calcium and magnesium are preferably included with the norepinephrine supplement and more preferably with both precursor supplements.
- An effective amount of copper e.g. as copper sebacate, is helpful in the production of norepinephrine from tyrosine and is included in the norepinephrine precursor supplement.
- Folic acid which facilitates the production of neurotransmitters, is generally included in an effective amount and preferably with the norepinephrine precursor supplement.
- choline e.g. as choline citrate
- choline citrate a precursor for the neurotransmitter acetylcholine and as an aid to increase uptake of magnesium.
- the choline is preferably included with the serotonin precursor supplement.
- An effective amount of a methyl donor e.g. dimethylglycine, is generally included and is preferably included with the serotonin precursor supplement.
- the daily supplements of serotonin and norepinephrine precursors can be formulated in a wide variety of formulations, as described hereinbefore, and that the following formulations are merely exemplary of such supplement formulation.
- the patients also preferably adjust or alter their dietary regime to avoid, as much as possible, an allergic reaction to food so as to inhibit or present release of histamine and other inflammatory chemicals.
- Examples 1 to 4 are examples of suitable daily serotonin precursor supplement formulations and Examples 5 and 6 are examples of suitable daily norepinephrine precursor supplement formulations.
- Each of the above ingredients is placed in a mortar and ground to a fine powder with a pestle.
- This formulation can be taken as a powder mixed with cold fruit juice, but the powder is generally placed into 3 suitable capsules and taken with cold fruit juice at bedtime, about 3-4 hours after the last daily meal. It is also possible to take additional dosages between meals on an empty stomach, if desirable.
- the ingredients are formed into a powder and optionally placed into 3 capsules and taken in the manner described in Example 1.
- the ingredients are formed into a powder and optionally placed into 3 capsules and taken in the manner described in Example 1.
- Each of the above ingredients is placed in a mortar and ground to a fine powder with a pestle.
- This formulation can be taken as a powder mixed with a suitable fluid, but the powder is generally placed into 3 suitable capsules and taken with a suitable fluid with or without food during the day.
- the ingredients are formed into a powder and optionally placed in capsules and taken in the manner described in Example 5.
- Example 7 to 9 the patients ingested approximately 180 mg L-5-hydroxytryptophan and from about 500 to 800 mg L-tyrosine daily in the formulation of Example 1 and 5 or 6.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (22)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/968,358 US5939076A (en) | 1997-11-12 | 1997-11-12 | Composition and method for treating or alleviating migraine headaches |
CA002309923A CA2309923A1 (en) | 1997-11-12 | 1998-11-10 | Composition and method for preventing or alleviating migraine headaches |
AU13985/99A AU1398599A (en) | 1997-11-12 | 1998-11-10 | Composition and method for preventing or alleviating migraine headaches |
PCT/US1998/024041 WO1999023881A1 (en) | 1997-11-12 | 1998-11-10 | Composition and method for preventing or alleviating migraine headaches |
GB0011925A GB2348133A (en) | 1997-11-12 | 1998-11-10 | Composition and method for preventing or alleviating migraine headaches |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/968,358 US5939076A (en) | 1997-11-12 | 1997-11-12 | Composition and method for treating or alleviating migraine headaches |
Publications (1)
Publication Number | Publication Date |
---|---|
US5939076A true US5939076A (en) | 1999-08-17 |
Family
ID=25514152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/968,358 Expired - Fee Related US5939076A (en) | 1997-11-12 | 1997-11-12 | Composition and method for treating or alleviating migraine headaches |
Country Status (5)
Country | Link |
---|---|
US (1) | US5939076A (en) |
AU (1) | AU1398599A (en) |
CA (1) | CA2309923A1 (en) |
GB (1) | GB2348133A (en) |
WO (1) | WO1999023881A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159505A (en) * | 1996-01-24 | 2000-12-12 | Piper; Edwina M. | Compositions for the treatment of migraine, containing potassium, magnesium and pyridoxine |
US6517832B1 (en) * | 2001-08-24 | 2003-02-11 | Jeffrey L. Marrongelle | Formulations and methods for treating chronic migraine |
US20030181509A1 (en) * | 2002-03-21 | 2003-09-25 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
US6685970B1 (en) * | 1999-09-21 | 2004-02-03 | Kyowa Hakko Kogyo Co., Ltd. | Compositions containing proanthocyanidin and a vitamin B6 derivative or a salt thereof |
US20040101575A1 (en) * | 1999-10-04 | 2004-05-27 | Hinz Martin C. | Comprehensive pharmacologic therapy for treatment of obesity |
US20040229285A1 (en) * | 2003-02-21 | 2004-11-18 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
US20040250723A1 (en) * | 2003-06-10 | 2004-12-16 | Heidelberger Druckmaschinen Ag | Method for metering dampening solution when printing with an offset press |
US6932988B2 (en) | 2002-09-16 | 2005-08-23 | Suzanne Cruse | Kit and method for migraine headache treatment |
US20060105023A1 (en) * | 2001-12-10 | 2006-05-18 | Knight Joseph R | Treatment of neurological disorders with nicotine |
US20060251752A1 (en) * | 2002-03-27 | 2006-11-09 | Hououdou Co., Ltd. | Compositions for treating and/or preventing pollinosis |
US20070065486A1 (en) * | 2004-05-21 | 2007-03-22 | Migco Limited | Migraine remedy |
US20070118211A1 (en) * | 2003-11-07 | 2007-05-24 | Gianluca Gazza | Method for preparing drug eluting medical devices and devices obtained therefrom |
US7268161B2 (en) | 1999-10-04 | 2007-09-11 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
US20080031869A1 (en) * | 2006-08-02 | 2008-02-07 | Fontaine Juliette S | Pain relief composition |
US20080139510A1 (en) * | 2006-12-07 | 2008-06-12 | Abe Rose | Treatment of migraine headaches with sublingual amino acids |
US20090234012A1 (en) * | 2002-03-21 | 2009-09-17 | Martin C. Hinz | Administration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
US20090311795A1 (en) * | 2002-03-21 | 2009-12-17 | Hinz Martin C | Bilateral control of functions traditionally regulated by only serotonin or only dopamine |
AU2004241889B2 (en) * | 2003-05-23 | 2010-09-16 | Migco Limited | Migraine remedy |
WO2016187277A1 (en) * | 2015-05-19 | 2016-11-24 | Joseph Robert Knight | Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUB20160516A1 (en) * | 2016-01-29 | 2017-07-29 | Volta Giorgio Dalla | Formulation and procedure |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029807A (en) * | 1975-03-27 | 1977-06-14 | Laboratorios Made, S.A. | Compounds 5-hydroxytryptophan glutamate and its derivatives |
US4299838A (en) * | 1974-12-23 | 1981-11-10 | La Cooperation Pharmaceutique Francaise | Tryptophan derivatives having an increased effect on the central nervous system |
US4377595A (en) * | 1979-08-13 | 1983-03-22 | Massachusetts Institute Of Technology | Process for reducing depression |
GB2113546A (en) * | 1982-01-22 | 1983-08-10 | Mayron International Inc | Treatment of migraine |
US4472387A (en) * | 1981-09-16 | 1984-09-18 | Panmedica S.A. | Pharmaceutical compositions capable of increasing cerebral serotonin concentration |
US4596807A (en) * | 1985-03-26 | 1986-06-24 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
US4639465A (en) * | 1985-08-30 | 1987-01-27 | Commonwealth Medical Corporation Of America | Method and composition for relieving pain |
US4650789A (en) * | 1985-10-15 | 1987-03-17 | Commonwealth Medical Corporation Of America | Method and composition for increasing production of serotonin |
US4698342A (en) * | 1985-07-16 | 1987-10-06 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
US4772591A (en) * | 1985-09-25 | 1988-09-20 | Peritain, Ltd. | Method for accelerated wound healing |
US4833154A (en) * | 1987-12-14 | 1989-05-23 | Jean Louis Louis J | Natural sleeping pill to prevent and alleviate insomnia |
US4853377A (en) * | 1985-10-15 | 1989-08-01 | Pollack Robert L | Method and composition for increasing production of serotonin |
US4897380A (en) * | 1985-08-30 | 1990-01-30 | Pollack Robert L | Method and composition for relieving dietary-related disorders |
US5189064A (en) * | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
US5250529A (en) * | 1990-02-08 | 1993-10-05 | Kos Pharmaceuticals, Inc. | Method alleviating migraine headache with mast cell degranulation blocking agents |
US5470846A (en) * | 1994-01-14 | 1995-11-28 | Sandyk; Reuven | Treatment of neurological and mental disorders |
-
1997
- 1997-11-12 US US08/968,358 patent/US5939076A/en not_active Expired - Fee Related
-
1998
- 1998-11-10 CA CA002309923A patent/CA2309923A1/en not_active Abandoned
- 1998-11-10 AU AU13985/99A patent/AU1398599A/en not_active Abandoned
- 1998-11-10 GB GB0011925A patent/GB2348133A/en not_active Withdrawn
- 1998-11-10 WO PCT/US1998/024041 patent/WO1999023881A1/en active Application Filing
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4299838A (en) * | 1974-12-23 | 1981-11-10 | La Cooperation Pharmaceutique Francaise | Tryptophan derivatives having an increased effect on the central nervous system |
US4029807A (en) * | 1975-03-27 | 1977-06-14 | Laboratorios Made, S.A. | Compounds 5-hydroxytryptophan glutamate and its derivatives |
US4377595A (en) * | 1979-08-13 | 1983-03-22 | Massachusetts Institute Of Technology | Process for reducing depression |
US4472387A (en) * | 1981-09-16 | 1984-09-18 | Panmedica S.A. | Pharmaceutical compositions capable of increasing cerebral serotonin concentration |
GB2113546A (en) * | 1982-01-22 | 1983-08-10 | Mayron International Inc | Treatment of migraine |
US4596807A (en) * | 1985-03-26 | 1986-06-24 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
US4698342A (en) * | 1985-07-16 | 1987-10-06 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
US5189064A (en) * | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
US4639465A (en) * | 1985-08-30 | 1987-01-27 | Commonwealth Medical Corporation Of America | Method and composition for relieving pain |
US4897380A (en) * | 1985-08-30 | 1990-01-30 | Pollack Robert L | Method and composition for relieving dietary-related disorders |
US4772591A (en) * | 1985-09-25 | 1988-09-20 | Peritain, Ltd. | Method for accelerated wound healing |
US4650789A (en) * | 1985-10-15 | 1987-03-17 | Commonwealth Medical Corporation Of America | Method and composition for increasing production of serotonin |
US4853377A (en) * | 1985-10-15 | 1989-08-01 | Pollack Robert L | Method and composition for increasing production of serotonin |
US4833154A (en) * | 1987-12-14 | 1989-05-23 | Jean Louis Louis J | Natural sleeping pill to prevent and alleviate insomnia |
US5250529A (en) * | 1990-02-08 | 1993-10-05 | Kos Pharmaceuticals, Inc. | Method alleviating migraine headache with mast cell degranulation blocking agents |
US5470846A (en) * | 1994-01-14 | 1995-11-28 | Sandyk; Reuven | Treatment of neurological and mental disorders |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159505A (en) * | 1996-01-24 | 2000-12-12 | Piper; Edwina M. | Compositions for the treatment of migraine, containing potassium, magnesium and pyridoxine |
US6685970B1 (en) * | 1999-09-21 | 2004-02-03 | Kyowa Hakko Kogyo Co., Ltd. | Compositions containing proanthocyanidin and a vitamin B6 derivative or a salt thereof |
US20050233008A1 (en) * | 1999-10-04 | 2005-10-20 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of a dysfunction |
US20040101575A1 (en) * | 1999-10-04 | 2004-05-27 | Hinz Martin C. | Comprehensive pharmacologic therapy for treatment of obesity |
US20060135567A1 (en) * | 1999-10-04 | 2006-06-22 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of obesity |
US7268161B2 (en) | 1999-10-04 | 2007-09-11 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
US7547723B2 (en) * | 1999-10-04 | 2009-06-16 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of a dysfunction |
US6517832B1 (en) * | 2001-08-24 | 2003-02-11 | Jeffrey L. Marrongelle | Formulations and methods for treating chronic migraine |
US20060105023A1 (en) * | 2001-12-10 | 2006-05-18 | Knight Joseph R | Treatment of neurological disorders with nicotine |
US20090234012A1 (en) * | 2002-03-21 | 2009-09-17 | Martin C. Hinz | Administration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
US20090311795A1 (en) * | 2002-03-21 | 2009-12-17 | Hinz Martin C | Bilateral control of functions traditionally regulated by only serotonin or only dopamine |
US20060178423A1 (en) * | 2002-03-21 | 2006-08-10 | Hinz Martin C | Serotonin and catecholamine system segment optimization technology |
US20030181509A1 (en) * | 2002-03-21 | 2003-09-25 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
US20080241278A1 (en) * | 2002-03-21 | 2008-10-02 | Hinz Martin C | Serotonin and catecholamine system segment optimization technology |
US20060251752A1 (en) * | 2002-03-27 | 2006-11-09 | Hououdou Co., Ltd. | Compositions for treating and/or preventing pollinosis |
US7569235B2 (en) * | 2002-03-27 | 2009-08-04 | Hououdou Co., Ltd. | Compositions for treating and/or preventing pollinosis |
US6932988B2 (en) | 2002-09-16 | 2005-08-23 | Suzanne Cruse | Kit and method for migraine headache treatment |
US20040229285A1 (en) * | 2003-02-21 | 2004-11-18 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
AU2004241889B2 (en) * | 2003-05-23 | 2010-09-16 | Migco Limited | Migraine remedy |
US20040250723A1 (en) * | 2003-06-10 | 2004-12-16 | Heidelberger Druckmaschinen Ag | Method for metering dampening solution when printing with an offset press |
US20070118211A1 (en) * | 2003-11-07 | 2007-05-24 | Gianluca Gazza | Method for preparing drug eluting medical devices and devices obtained therefrom |
US20070065486A1 (en) * | 2004-05-21 | 2007-03-22 | Migco Limited | Migraine remedy |
US20080031869A1 (en) * | 2006-08-02 | 2008-02-07 | Fontaine Juliette S | Pain relief composition |
US20080139510A1 (en) * | 2006-12-07 | 2008-06-12 | Abe Rose | Treatment of migraine headaches with sublingual amino acids |
WO2016187277A1 (en) * | 2015-05-19 | 2016-11-24 | Joseph Robert Knight | Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids |
Also Published As
Publication number | Publication date |
---|---|
AU1398599A (en) | 1999-05-31 |
WO1999023881A1 (en) | 1999-05-20 |
GB2348133A (en) | 2000-09-27 |
CA2309923A1 (en) | 1999-05-20 |
GB0011925D0 (en) | 2000-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5939076A (en) | Composition and method for treating or alleviating migraine headaches | |
US6821536B2 (en) | Antioxidative compositions | |
US7569239B2 (en) | Antioxidative compositions | |
US11478506B2 (en) | Dietary supplements | |
US20040005368A1 (en) | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite | |
EP1258245A2 (en) | Accelerated release composition containing bromocriptine | |
US20060233892A1 (en) | Topiramate compositions for treatment of headache | |
AU2003282829B2 (en) | Antioxidative Compositions | |
CA2274839A1 (en) | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions | |
WO2008079876A1 (en) | Methods and kits for co-administration of nutritional supplements | |
EP0814816A1 (en) | Compositions for the treatment of migraine, containing potassium, magnesium and pyridoxine | |
EP0288447A1 (en) | Composition for the treatment of migraine, by influencing thenerve cells. | |
CA2427618A1 (en) | Composition containing statins and calcium for improved cardiovascular health | |
US20020048612A1 (en) | GABA substrate and the use thereof for treating cognitive and emotional disorders | |
US20060105033A1 (en) | Dietary composition containing conjugated linoleic acid and calcium for improved health | |
TW200913988A (en) | Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient | |
US7270840B2 (en) | Antioxidative compositions | |
KR20190041483A (en) | Composition for treating hangover | |
NO20001717L (en) | Serotonin-containing formulation for oral administration and use of the same | |
JPH11255656A (en) | Therapeutic composition for atopic dermatitis | |
US20040097429A1 (en) | Method for the reduction of the mammalian appetite | |
Raffaelli Jr et al. | Lisuride in cluster headache | |
US4650668A (en) | Composition for relieving toothache pain and other forms of intense pain | |
CA2427681A1 (en) | Dietary composition containing conjugated linoleic acid and calcium for improved health | |
AU5800900A (en) | Medicament for treatment of neuropathies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALLOCCA TECHNICAL, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALLOCCA, JOHN A.;REEL/FRAME:008817/0719 Effective date: 19971106 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: ALLOCCA BIOTECHNOLOGY, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALLOCCA TECHNICAL, INC.;REEL/FRAME:013727/0509 Effective date: 19991001 Owner name: DYNAMIC HEALTH RESOURCES, LLC, VIRGINIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALLOCCA BIOTECHNOLOGY, INC.;REEL/FRAME:013727/0520 Effective date: 20030101 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20110817 |